Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Syndax's Newly Arrived CEO Briggs Morrison Announces Clinical Collaboration With Genentech

This article was originally published in Scrip

Executive Summary

Syndax Pharmaceuticals Inc. - which recently lured respected scientist Briggs Morrison away from AstraZeneca to be its CEO - has entered a clinical collaboration with Genentech Inc. to evaluate the safety, tolerability and preliminary efficacy of its lead asset, entinostat, an oral small molecule targeting immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with the Roche Holding AG biologics division's PD-L1 inhibitor atezolizumab in patients with triple-negative breast cancer.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts